BioNTech (BNTX)
(Delayed Data from NSDQ)
$87.21 USD
+0.50 (0.58%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $87.20 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BNTX 87.21 +0.50(0.58%)
Will BNTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNTX
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump
Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?
Other News for BNTX
WHO picks JN.1 variant for next set of COVID vaccines
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
What's Going On With Pfizer Stock On Thursday?
GSK sues Pfizer, BioNTech over COVID-19 vaccines patents
Baron Focused Growth Fund Q1 2024 Shareholder Letter